Opendata, web and dolomites

Nanosynex SIGNED

Ultra-fast Antimicrobial Susceptibility Test for diagnosing antimicrobial resistance to provide personalized antibiotic treatments

Total Cost €


EC-Contrib. €






Project "Nanosynex" data sheet

The following table provides information about the project.


Organization address
address: METSADA 7 ST
postcode: 5126112
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NANOSYNEX LTD IL (BNEI BRAK) coordinator 50˙000.00


 Project objective

Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR. Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e., in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60 countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSYNEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSYNEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)


Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More